drugset / Trial / NCT05623410
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.
Timeline
- Start
- 2022-10-11
- Primary completion
- 2023-02-10
- Completion
- 2023-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATGC-110 | Protein / enzyme biologic | 20 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
Indications
No indication recorded.